Chronic kidney disease (CKD) is a leading global cause of mortality, often linked with non-communicable diseases such as diabetes, cardiovascular disease, and cancer. Effective treatments to halt kidney fibrosis remain lacking. Macrophage–Myofibroblast Transition (MMT) is a critical driver of CKD progression. This study aimed to develop a novel therapeutic strategy targeting MMT by inhibiting its key regulator, the neuronal transcription factor Pou4f1.
Chung et al. (Wed,) studied this question.